Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple Immunotherapy for Relapsed/Refractory Neuroblastoma
NCT05754684Phase 2Recruiting
- Sponsor
- Hong Kong Children’s Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Small Molecules, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cell therapy, Dinutuximab beta, spironolactone in neuroblastoma, sponsored by Hong Kong Children’s Hospital. Started Jan 2022; status: recruiting.
02
Drugs
haploidentical natural killer cell therapyDinutuximab betaspironolactone
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05754684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754684.